MDL-201

MDL-201 is an investigational epigenome editing therapy being developed by Modalis Therapeutics for the treatment of Duchenne Muscular Dystrophy (DMD). The drug utilizes Modalis's proprietary CRISPR-GNDM (Gene/locus-specific Nucleotide-sequence Demethylation and/or transcriptional activation Module) technology, which is an epigenetic gene editing platform that modulates gene expression without DNA cleavage. MDL-201 is specifically designed to upregulate the expression of utrophin, a fetal homolog of dystrophin, to compensate for the absence of functional dystrophin in DMD patients. By targeting the utrophin gene rather than the mutated dystrophin gene, MDL-201 represents a mutation-agnostic approach to treating DMD. The therapy is currently in the IND-enabling stage of development.